Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned an average rating of “Moderate Buy” from the four analysts that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $85.25.

PBH has been the topic of several recent research reports. DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th.

Prestige Consumer Healthcare Stock Up 0.9 %

Prestige Consumer Healthcare stock opened at $74.45 on Friday. The stock has a market cap of $3.68 billion, a P/E ratio of 18.11, a P/E/G ratio of 2.32 and a beta of 0.51. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare has a twelve month low of $58.22 and a twelve month high of $86.36. The company’s 50-day moving average price is $80.56 and its two-hundred day moving average price is $74.17.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same period last year, the firm earned $1.07 earnings per share. The business’s revenue for the quarter was down .9% on a year-over-year basis. As a group, analysts expect that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the transaction, the senior vice president now owns 18,835 shares in the company, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last quarter. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently modified their holdings of PBH. Victory Capital Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 9.0% during the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after purchasing an additional 171,357 shares during the period. Arizona State Retirement System lifted its holdings in shares of Prestige Consumer Healthcare by 1.9% during the second quarter. Arizona State Retirement System now owns 13,900 shares of the company’s stock worth $957,000 after purchasing an additional 264 shares during the period. Norden Group LLC lifted its holdings in shares of Prestige Consumer Healthcare by 25.9% during the second quarter. Norden Group LLC now owns 12,435 shares of the company’s stock worth $856,000 after purchasing an additional 2,559 shares during the period. Quest Partners LLC lifted its holdings in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares during the period. Finally, Choreo LLC acquired a new position in Prestige Consumer Healthcare in the second quarter valued at $677,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.